645372-27-6

Basic information

• Product Name: CYCLOPENTYLHYDRAZINE DIHYDROCHLORIDE
• Synonyms: CYCLOPENTYLHYDRAZINE DIHYDROCHLORIDE;Hydrazine, cyclopentyl-, dihydrochloride;1-cyclopentylhydrazine dihydrochloride;1-CYCLOPENTYLHYDRAZINE 2HCL
• CAS NO: 645372-27-6
• Molecular Formula: C5H14Cl2N2
• Molecular Weight: 173.08
• Mol File: 645372-27-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 268 °C at 760 mmHg
• Flash Point: 115.9 °C
• Appearance: /
• Vapor Pressure: 0.00615mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: CYCLOPENTYLHYDRAZINE DIHYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOPENTYLHYDRAZINE DIHYDROCHLORIDE(645372-27-6)
• EPA Substance Registry System: CYCLOPENTYLHYDRAZINE DIHYDROCHLORIDE(645372-27-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 645372-27-6(Hazardous Substances Data)

Usage

General Description

CYCLOPENTYLHYDRAZINE DIHYDROCHLORIDE is a chemical compound that is used in the pharmaceutical industry for its potential applications in the treatment of cancer and other diseases. It is a hydrazine derivative that has shown promising results in preclinical studies for its anti-tumor and anti-metastatic properties. CYCLOPENTYLHYDRAZINE DIHYDROCHLORIDE is believed to work by inhibiting the growth and spread of cancer cells by targeting specific molecular pathways. CYCLOPENTYLHYDRAZINE DIHYDROCHLORIDE is still in the early stages of research and development, but it holds potential for the future development of new cancer treatments.

InChI:InChI=1/C5H12N2.2ClH/c6-7-5-3-1-2-4-5;;/h5,7H,1-4,6H2;2*1H

Upstream product

• 120-92-3 cyclopentanone 
• 287729-05-9 N-cyclopentyl-N-tert-butyloxycarbonylaminophthalimide 
• 96-41-3 Cyclopentanol 
• 79201-39-1 tert-butyl 2-cyclopentylidenehydrazine carboxylate 
• 259870-74-1 tert-butyl 1-cyclopentylhydrazinecarboxylate 
• 646071-31-0 tert-butyl 2-cyclopentylhydrazinecarboxylate 

Downstream Products

• 89169-57-3 6-Methoxy-1,2,3,4-tetrahydrocyclopentaindole 
• 1426534-38-4 C₂₁H₂₄N₂O 

Relevant articles and documents

Decarboxylative hydrazination of unactivated carboxylic acids by cerium photocatalysis

We report the cerium photocatalyzed radical decarboxylative hydrazination of carboxylic acids with di-tert-butylazodicarboxylate (DBAD). The operationally simple protocol provides rapid access to synthetically useful hydrazine derivatives and overcomes current scope limitations in the photoredox-catalyzed decarboxylation of carboxylic acids.

Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease

The invention provides compounds of Formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein A, P, J, x, and R10 are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including, diabetes, including type 1 and type 2 diabetes, hyperglycemia, dyslipidemia, impaired glucose tolerance, metabolic syndrome, and/or cardiovascular disease.